Pors K - Search Results

1

Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.

Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, Alandas MN, Cooper PA, Searcey M, Pors K, Shnyder SD, Patterson LH. Sutherland M, et al. Among authors: pors k. Mol Cancer Ther. 2013 Jan;12(1):27-37. doi: 10.1158/1535-7163.MCT-12-0405. Epub 2012 Oct 1. Mol Cancer Ther. 2013. PMID: 23033491

2

Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer.

Pors K, Paniwnyk Z, Teesdale-Spittle P, Plumb JA, Willmore E, Austin CA, Patterson LH. Pors K, et al. Mol Cancer Ther. 2003 Jul;2(7):607-10. Mol Cancer Ther. 2003. PMID: 12883032

3

Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells.

Pors K, Paniwnyk Z, Ruparelia KC, Teesdale-Spittle PH, Hartley JA, Kelland LR, Patterson LH. Pors K, et al. J Med Chem. 2004 Mar 25;47(7):1856-9. doi: 10.1021/jm031070u. J Med Chem. 2004. PMID: 15027879

4

Truncated azinomycin analogues intercalate into DNA.

Casely-Hayford MA, Pors K, Patterson LH, Gerner C, Neidle S, Searcey M. Casely-Hayford MA, et al. Among authors: pors k. Bioorg Med Chem Lett. 2005 Feb 1;15(3):653-6. doi: 10.1016/j.bmcl.2004.11.037. Bioorg Med Chem Lett. 2005. PMID: 15664831

5

Design and synthesis of a DNA-crosslinking azinomycin analogue.

Casely-Hayford MA, Pors K, James CH, Patterson LH, Hartley JA, Searcey M. Casely-Hayford MA, et al. Among authors: pors k. Org Biomol Chem. 2005 Oct 7;3(19):3585-9. doi: 10.1039/b508908e. Epub 2005 Sep 5. Org Biomol Chem. 2005. PMID: 16172698

6

Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells.

Pors K, Plumb JA, Brown R, Teesdale-Spittle P, Searcey M, Smith PJ, Patterson LH. Pors K, et al. J Med Chem. 2005 Oct 20;48(21):6690-5. doi: 10.1021/jm050438f. J Med Chem. 2005. PMID: 16220985

7

DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents.

Pors K, Patterson LH. Pors K, et al. Curr Top Med Chem. 2005;5(12):1133-49. doi: 10.2174/156802605774370883. Curr Top Med Chem. 2005. PMID: 16248788 Review.

8

Synthesis of DNA-directed pyrrolidinyl and piperidinyl confined alkylating chloroalkylaminoanthraquinones: potential for development of tumor-selective N-oxides.

Pors K, Shnyder SD, Teesdale-Spittle PH, Hartley JA, Zloh M, Searcey M, Patterson LH. Pors K, et al. J Med Chem. 2006 Nov 30;49(24):7013-23. doi: 10.1021/jm0608154. J Med Chem. 2006. PMID: 17125254

9

Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products.

Ghosh N, Sheldrake HM, Searcey M, Pors K. Ghosh N, et al. Among authors: pors k. Curr Top Med Chem. 2009;9(16):1494-524. doi: 10.2174/156802609789909812. Curr Top Med Chem. 2009. PMID: 19903166 Review.

10

Use of the hollow fiber assay for the evaluation of DNA damaging agents.

Veiga JP, Cooper PA, Pors K, Patterson LH, Bibby MC, Shnyder SD. Veiga JP, et al. Among authors: pors k. J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):226-32. doi: 10.1016/j.vascn.2011.04.006. Epub 2011 Apr 30. J Pharmacol Toxicol Methods. 2011. PMID: 21569858

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

62 results

Search Page